ExoVectory awarded Eurostars grant for ex vivo engineering of therapeutic T-cells

ExoVectory in collaboration with UMC Utrecht, Utrecht University and EVerZom is awarded with the Eurostars grant - total value project €1,5Mio - for their innovative approach to developing an ex vivo engineered T-cell therapy against cancer.


About the consortium

ExoVectory is pioneering an advanced technology facilitating the efficient loading of DNA and ribonucleoprotein particles into extracellular vesicles (EVs) for CRISPR/Cas9-based genome editing, particularly for the ex vivo engineering of therapeutic T-cells. With University Medical Center Utrecht (UMCU) specialized in EV isolation and characterization, and French SME EVerZom excelling in scalable and clinically compatible EV manufacturing technology, the EVECTOR consortium is joining forces to develop an unparalleled delivery system for therapeutic gene editing.

What is the project about?

While viral vectors are the gold standard for gene therapies, they come with significant safety and implementation constraints. EVs present a promising alternative but are currently hindered by challenges in accommodating nucleic acids or proteins within them, as well as cost-effective production. The EVECTOR project aims to overcome these obstacles. Through the consortium’s innovative approach, we are getting one step closer towards personalized healthcare with more effective treatments and fewer side effects.


Eurostars, a program initiated by Eureka, is a funding platform aimed at supporting innovative small and medium-sized enterprises in collaborative research and development projects across Europe.


ExovectoryFFUND, and LinkedIn


eurostars beeldje exovectory

‹ News overview